LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on spinocerebellar ataxia. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat spinocerebellar ataxia.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Spinocerebellar ataxia: Market overview
Spinocerebellar ataxia (SCA) is a hereditary disease caused due to mutations in the ATXN1 gene. Mutation in ATXN1 gene can lead to degenerative changes in the cerebellum and spinal cord. A person affected by the disease usually inherits the altered gene from an affected parent. The gene is passed down from one generation to the next.
According to a senior market research analyst at Technavio, “The National Institutes of Health stated in their research that one to two per 100,000 people worldwide are affected by spinocerebellar ataxia. Spinocerebellar ataxia type 3, also called the Machado-Joseph disease, is an inherited form of ataxia that is characterized by the progressive clumsiness in arms and legs. The MJD can be segmented into three types such as Type I, type II, and type III.”
Spinocerebellar ataxia: Segmentation analysis
This pipeline analysis report segments the spinocerebellar ataxia market based on RoA (IV, oral, and sublingual), therapeutic modality (small molecule, gene therapy, and stem cell), geographical segmentation (Israel, Japan, Taiwan, and US) and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modalities, close to 64% of the molecules that are being investigated for the treatment of spinocerebellar ataxia are small molecules.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
